Cross-Border Impact Ventures is a North American health tech impact fund.
Portfolio
3
companies
OXcan
Oxford Cancer Analytics develops blood tests for early cancer detection.
Oxford Cancer Analytics
Oxford Cancer Analytics develops blood tests for early cancer detection using proteomics and artificial intelligence.
TidalSense
TidalSense manufactures handheld diagnostic devices that detect chronic obstructive pulmonary disease from normal breathing.
Annie Theriault
Managing Partner
Annie serves as managing partner at Cross-Border Impact Ventures and previously held investment leadership roles at Grand Challenges Canada and Grenville Strategic Royalty Corp.
LinkedInDonna Parr
Managing partner
Cross-Border Impact Ventures led the round, which will fund international expansion and product development.
"We’re still diagnosing in the twenty-first century with a test invented in the 1800s, and one that needs specialist equipment and training most of the world doesn’t have access to. Lower-income and minority communities pay the price for that first. That’s the gap we want to close at TidalSense, and the NHS is the first place we’re doing it,"
The round was led by We Venture Capital and Cross-Border Impact Ventures to support the development of liquid biopsy tests.
"The power of the OXcan proteomics biomarker discovery platform and the data generated by Oxcan stand out against the backdrop of other liquid biopsy companies, indicating a truly superior performance in the identification of early stage lung cancer"
The round was led by We Venture Capital and Cross-Border Impact Ventures to fund the global commercialisation of its liquid biopsy technology.
"Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy. Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes."
